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Aims It is unknown whether subclinical high-altitude pulmonary oedema reduces spontaneously after prolonged altitude
exposure. Continuous positive airway pressure (CPAP) removes extravascular lung fluids and improves haemoglobin
oxygen saturation in acute cardiogenic oedema. We evaluated the presence of pulmonary extravascular fluid increase
by assessing CPAP effects on haemoglobin oxygen saturation under acute and prolonged altitude exposure.
Methods
and results
We applied 7 cm H2O CPAP for 30 min to healthy individuals after acute (Capanna Margherita, CM, 4559 m, 2 days
permanence, and ,36 h hike) and prolonged altitude exposure (Mount Everest South Base Camp, MEBC, 5350 m,
10 days permanence, and 9 days hike). At CM, CPAP reduced heart rate and systolic pulmonary artery pressure while
haemoglobin oxygen saturation increased from 80% (median), 78–81 (first to third quartiles), to 91%, 84–97
(P, 0.001). After 10 days at MEBC, haemoglobin oxygen saturation spontaneously increased from 77% (74–82)
to 86% (82–89) (P, 0.001) while heart rate (from 79, 64–92, to 70, 54–81; P, 0.001) and respiratory rate
(from 15, 13–17, to 13, 13–15; P, 0.001) decreased. Under such conditions, these parameters were not influenced
by CPAP.
Conclusion After ascent excessive lung fluids accumulate affecting haemoglobin oxygen saturation and, in these circumstances,
CPAP is effective. Acclimatization implies spontaneous haemoglobin oxygen saturation increase and, after prolonged
altitude exposure, CPAP is not associated with HbO2-sat increase suggesting a reduction in alveolar fluids.
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Introduction
High-altitude pulmonary oedema (HAPE) is observed in 2–5% of
low landers when climbing1,2 and, most frequently, within 1–3
days after arrival at altitude.3 HAPE is more frequent if ascent is
rapid,1,4 associated with heavy exercise5,6 and in the so-called sus-
ceptible subjects usually defined as subjects with a previous history
of HAPE.7–9 At altitude, HAPE-susceptible subjects have some pul-
monary haemodynamic derangement even in the absence of any
clinical manifestation of HAPE.8 A higher risk of HAPE is also
reported in subjects with smaller lungs and higher pulmonary vas-
cular pressure,10–12 probably due to the relationship between pul-
monary artery pressure changes and vascular cross-sectional
area.10 So, albeit clinically overt HAPE is relatively rare, it has
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been suggested that subclinical interstitial oedema is present in
most recreational and professional climbers.10,13 Indeed,
Cremona et al.10 observed that three out of every four subjects,
after rapid ascent to a high altitude, have an increase in closing
volume which they related to increased pulmonary extravascular
fluids, whereas Grocott et al.13 reported an increased alveolar–
arterial oxygen pressure gradient at least at an extreme altitude.
At present, no definite information is available about the effects
of a prolonged permanence at a high altitude on acute extravascu-
lar pulmonary fluid increase.
High-altitude pulmonary oedema is, at least at its onset, a haemo-
dynamic hydrostatic oedema characterized by high pulmonary
artery pressure.7,8,14,15 So, in this regard, it is similar to cardiogenic
oedema observed in patients at sea level. Cardiogenic pulmonary
oedema is frequently treated using positive pressure ventilation
[continuous positive airway pressure (CPAP)],16–18 and also
HAPE could benefit from this intervention, starting from the
pioneering personal experience of Oelz.19 Indeed, CPAP in the
presence of increased extra vascular lung fluid, allows improvement
of oxygen transport across the alveolar capillary membrane by
mechanical removal of accumulated alveolar fluid.19–21
The present research project was undertaken to assess the effects
of CPAP on arterial haemoglobin oxygen saturation in subjects after
either a rapid ascent to high altitudes and after a more gradual ascent
followed by prolonged sojourn at high altitudes. The former exper-
iments were performed at Capanna Regina Margherita (CM,
4559 m) which was reached from sea level in less than 2-day hike
with CPAP effects being assessed on the second day of altitude
exposure. The latter experiments were performed at Mount
Everest South Base Camp (MEBC, 5400 m) reached with a 9-day
hike, with CPAP effects being assessed 10 days after arrival at
MEBC. The final aim of our study was to indirectly evaluate the
degree of pulmonary extravascular fluid increase under acute or
prolonged exposure to high-altitude hypoxia by assessing the
effects of CPAP on HbO2-sat in these conditions.
Methods
In all conditions of our study, we included subjects who, at the time of
CPAP application, showed no evidence of HAPE. Continuous positive
airway pressure effects at CM were assessed within the frame of the
2005 Monte Rosa Research Expedition which included a group of
39 subjects. During this expedition, subjects did not receive any
research drug. Twenty-three out of 39 subjects were randomly
assigned to CPAP application. Continuous positive airway pressure
effects at MEBC were assessed within the frame of the HIGHCARE
(HIGH altitude CArdiovascular REsearch) project, which included a
total of 47 subjects. In this project, subjects were randomized to
receive an angiotensin II receptor blocker (Telmisartan 80 mg, n ¼
24) or placebo (n ¼ 23). Sixteen out of these 47 subjects were ran-
domly assigned to CPAP application (eight under telmisartan; eight
under placebo) (Table 1). Subjects not involved in the CPAP studies,
both at CM and MEBC, had the same characteristics of the subjects
involved in the CPAP studies (Table 1). High-altitude sickness preven-
tion by any drug was not allowed in both CM and MEBC
expeditions.22,23 At sea level, before ascent to a high altitude, a
general safety medical check-up was performed on all subjects at
S. Luca Hospital in Milan (Italy).
High-altitude ascent technique
and laboratory setting
Capanna Margherita is located on the top of one of the Monte Rosa
peaks in the Swiss-Italian Alps at an altitude of 4559 m. Capanna
Margherita was reached from Alagna Valsesia (altitude 1130 m) with
subjects ascending first by cable-car up to Punta Indren (3200 m)
and then on foot to the Gnifetti hut (altitude 3647 m). After an over-
night stay, the hike was continued up to CM. All subjects arrived at CM
in less than 36 h from initial departure.24 CPAP experiments were
done the day after arrival at CM. Mount Everest South Base Camp is
located at 5400 m on the south wing of Mt Everest (Nepal), on the
‘Ice Fall Glacier’. Mount Everest South Base Camp was reached
during a 9-day hike. We moved from Kathmandu (1200 m) to Lukla
(2800 m) by plane and reached Namche Bazar (3500 m) the same
day by helicopter. We stopped 3 days in Namche Bazar for initial
research/safety measurements and acclimatization. Following a 2 days
hike, we then reached Periche (4200 m) where we stopped 1 day
for further acclimatization. Thereafter, with a further 2 days hike, we
reached MEBC. Experiments at Monte Rosa were performed in CM,
a comfortable heated hut, at 4559 m.7,8,24 Experiments at MEBC
were performed at 5400 m in a heated tent, fortunately on 2 sunny
days with a warm temperature. In both conditions, subjects were
made as comfortable as possible and in no case did they complain of
any sort of discomfort due to cold temperatures during the research
measurements. In both CM and MEBC, laboratory temperature and
barometric pressure were recorded.
During the HIGHCARE Expedition, a safety check was performed in
the morning between the first and the second day after arrival at
Namche Bazar and at MEBC, as well as between Days 10 and 11 of per-
manence atMEBC.During these checks, wemeasured several parameters
including heart rate, systemic blood pressure, respiratory rate, and pul-
monary artery blood pressure by echocardiography. Mountain sickness
severity was assessed by means of the Lake Louise Score (LLS).25
Continuous positive airways pressure
ventilation
Continuous positive airways pressure was applied using a nasal mask
(HC405 Fisher & Pikel, Aukland, New Zealand) in a sitting position
using a standard commercial instrument (S8 ResMed, Bella Vista,
Australia) regulated to administer a pressure of 7 cm H2O.
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Table 1 Anthropometric data of subjects
Capanna Regina
Margherita
Mount Everest
South Base
Camp
P-value
Subjects involved in the CPAP studies
Sex (M/F) 17/6 15/1 0.21
Age (years) 42 (32–53) 47 (42–53) 0.20
BMI 23 (22–25) 24 (21–25) 0.70
Subjects not involved in the CPAP studies.
Sex (M/F) 13/3 16/13 0.06
Age (years) 34 (30–60) 36 (32–41) 0.27
BMI 23 (21–24) 24 (21–24) 0.49
Age and BMI data are reported as median and inter-quartile range (first and third
quartiles). M, male; F, female; BMI, body mass index. Sex differences were analysed
by Fisher’s test; age and BMI differences by Wilcoxon rank-sum test.
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Transcutaneous haemoglobin oxygen saturation was measured con-
stantly before, during, and after CPAP application (pulse oxymeter,
Life Scope I, Nihon Kohden, Tokyo, Japan). Pulmonary pressure was
measured before and immediately after CPAP application by means
of Doppler Ultrasound (Vivid I; General Electric, Tirat Carmel,
Israel). Systemic blood pressure (by an oscillometric validated device,
OMRON M5-I, Omron, Tokyo, Japan), heart rate, and respiratory fre-
quency were also recorded at the same times.
At MEBC, on the day following the 7 cm H2O CPAP (Day 22 of
ascension), four subjects also underwent 15 cm H2O CPAP application
for 30 min, to explore the possibility of a greater effect with a higher
positive airway pressure.
Statistical analysis
Subjects were selected for the CPAP experiments, both at CM and
MEBC, by means of a computer-generated randomization list. Assuming
a standard deviation of 6 (%) for the main outcome (SpO2), the sample
size of 23 subjects in the study at CM allowed a statistical power of
approximately 80% to assess as significant, with a two-tailed a ¼ 0.05,
a within-subject difference of about 4 (%) (allowing a 20% excess
number of subjects, due to the use of a non-parametric test). For the
study at MEBC, the sample size of 16 subjects allowed the same statisti-
cal power to assess as significant a within subject difference of about 5
(%). Owing to the relatively limited sample size allowed by the difficult
experimental conditions, and to the skewed distribution of most of
the examined variables, data are summarized as median and inter-
quartile range. Data were analysed using non-parametric tests. Within
the group, variations were assessed using the Wilcoxon signed-rank
test; between-group comparisons were made using the Wilcoxon
rank-sum test. Gender distribution between the two groups was evalu-
ated using the Fisher test. Changes during high-altitude exposure in the
Mt Everest expedition were assessed by repeated measurements, non-
parametric Friedman test followed by post hoc analysis corrected by the
Bonferroni method. P, 0.05 were considered as significant. All tests
were two-sided and were performed using SAS statistical package
V9.13 (SAS Institute Inc., Cary, NC, USA).
Results
Anthropometric data for subjects at CM and MEBC were not
different (Table 1). Sex distribution difference did not reach
statistical significance and did not influence the CPAP response.
Mean atmospheric pressure and oxygen air pressure were 440
and 92 mmHg at CM and 400 and 84 mmHg at MEBC during
CPAP experiments. All subjects who underwent 7 cm H2O
CPAP tolerated the manoeuvre well, both at CM and MEBC.
Before CPAP at MEBC, telmisartan and placebo-treated subjects
did not differ in terms of haemoglobin oxygen saturation, heart
rate, respiratory rate, and systemic and pulmonary blood pressure,
respectively (Table 2). The response to CPAP was similar, so that
data are reported regardless of treatment. Subjects who did not
participate in the CPAP research protocol, both at CM and
MEBC, had cardiorespiratory parameters similar to those of sub-
jects who participated in the CPAP protocol.
After short-term high-altitude exposure at CM, application of
7 cm H2O CPAP for 30 min reduced heart rate and systolic pul-
monary artery pressure but did not influence systemic blood
pressure (Table 3), whereas haemoglobin oxygen saturation was
significantly increased by CPAP from 80 to 91% (P, 0.001). Hae-
moglobin oxygen saturation increase became evident 5 min after
starting CPAP application and remained so throughout (Figure 1).
On the contrary, after long-term high-altitude exposure at MEBC
none of the above-reported parameters was influenced by CPAP
(Table 3, Figure 1). Specifically, haemoglobin oxygen saturation
was 81 and 80% before CPAP and after 30 min of 7 cm H2O
CPAP, respectively. As an average, comparing pre-CPAP con-
ditions under short-term high-altitude exposure with those at pro-
longed high-altitude exposure, heart rate was the only parameter
evaluated that was different (Table 3). Interestingly, average haemo-
globin oxygen saturation was the same in the two pre-CPAP con-
ditions. At CM, neither LLS, haemoglobin oxygen saturation nor
pulmonary vascular pressure correlated to the haemoglobin
oxygen saturation changes during CPAP.
Lake Louise Score was 3.5 (2.0–4.8) at CM and 0.0 (0.0–0.2)
after 10 days stay at MEBC (P, 0.001).25
Haemoglobin oxygen saturation, heart rate, and respiratory rate
varied during chronic adaptation to high altitudes in the HIGHCARE
expedition. In Figure 2, data collected at Milan (95 m), Namche Bazar
(3500 m, i.e. on Days 2 and 3 of ascent towards MEBC), on Days 1
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Table 2 Cardiorespiratory parameters after 10 days at Mount Everest South Base Camp
Telmisartan subjects (n5 8) Placebo subjects (n5 8) D Pre-CPAP and 300
CPAP telmisartan vs.
placebo (P-value)
Pre-CPAP 300 CPAP 300
Post-CPAP
Pre-CPAP CPAP 300
Post-CPAP
HbO2-sat (%) 84 (78–85) 81 (78–87) 83 (78–88) 81 (77–83) 80 (76–83) 81 (78–84) 0.94
HR (b.p.m.) 74 (70–92) 70 (65–81) 75 (66–85) 78 (67–85) 75 (63–85) 72 (66–80) 0.24
RR (b.p.m.) 11 (9–13) 13 (11–16) 15 (13–16) 16 (13–20) 14 (10–18) 13 (18–17) 0.14
SBP (mmHg) 126 (113–147) 125 (101–145) 127 (119–137) 136 (123–142) 132 (123–139) 140 (124–152) 0.29
DBP (mmHg) 80 (70–86) 76 (71–91) 80 (78–81) 79 (71–90) 86 (84–92) 88 (84–93) 0.29
PAPs (mmHg) 31 (26–36) 31 (24–36) 31 (22–35) 35 (29–41) 37 (36–38) 34 (33–38) 0.94
Data are reported as median and inter-quartile range (first and third quartiles). CPAP, continuous positive pressure ventilation. Continuous positive airway pressure data were
collected on continuous positive airway pressure at the end of 30 min continuous positive airway pressure application. HbO2-sat, arterial haemoglobin saturation for oxygen; HR,
heart rate; RR, respiratory rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; PAPs, pulmonary artery systolic pressure. In the last right column, P-values for
differences between pre-continuous positive airway pressure and 300 continuous positive airway pressure in subjects assuming telmisartan vs. subjects assuming placebo are
reported.
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and 2 at MEBC (5350 m, Days 10 and 11 of ascent) and on Days 11
and 12 at MEBC (Days 21 and 22 of ascent) are reported. At
MEBC after 10 days, haemoglobin oxygen saturation increased
(from 77 to 86%; P, 0.001) whereas heart rate (from 79 to
70 b.p.m.; P, 0.001) and respiratory rate (from 15 to 13 breaths/
min; P, 0.001) decreased. Lake Louise Score during ascent and
MEBC stay is also reported in Figure 2.
Four subjects underwent 15 cm CPAP application at MEBC.
One subject did not tolerate 15 cm H2O CPAP. In the remaining
three, haemoglobin oxygen saturation was 78% before CPAP and
74% during CPAP (30 min). Heart rate, respiratory rate, and sys-
temic and pulmonary pressures did not show any significant
change.
Discussion
These data show that CPAP application after short-term high-
altitude exposure improves arterial haemoglobin oxygen satur-
ation, whereas this is not the case in subjects after prolonged
high-altitude exposure, even when pre-CPAP haemoglobin
oxygen saturation is similar to the acute condition.
These findings suggest that acutely, in line with our hypothesis,
some lung fluid accumulation is, at least in part, responsible for
low arterial haemoglobin oxygen saturation at high altitudes, but
that after prolonged high-altitude exposure no more extravascular
fluid is present on the alveolar-capillary membrane which could be
shifted away by CPAP.
CPAP is recommended and frequently used for pulmonary
oedema treatment at sea level.16–18 In acute pulmonary oedema,
CPAP usually leads to a rapid increase in haemoglobin oxygen satur-
ation. It has been proposed that CPAP acts by shifting excessive lung
fluid from the flat part of the alveolar-capillary membrane, where
the majority of gas exchange takes place, to the alveolar corner
and from there to the extra-alveolar interstitial space.20,21 This
suggested lung fluid shift, although the total amount of lung fluid
does not change, may be the factor responsible for the observed
improvement in haemoglobin oxygen saturation in patients with
acute pulmonary oedema treated with CPAP.20,21,26–28
High-altitude pulmonary oedema occurs in a percentage of sub-
jects who reach high altitude, usually 24–72 h after arrival and par-
ticularly if the ascent is associated with heavy physical exercise, as it
was the case in our study at CM.1–5 High-altitude pulmonary
oedema has a pulmonary haemodynamic involvement that
resembles that observed during acute pulmonary oedema at sea
level.7–9,15 Furthermore, Cremona et al.10 produced indirect evi-
dence suggesting that many, if not all, subjects who ascend to
high altitudes show evidence of lung fluid increase and, very
recently, Grocott et al.13 showed, albeit at extreme altitude, an
increase in alveolar–arterial oxygen pressure gradient. Accord-
ingly, studies of both Cremona et al.10 and Grocott et al.13 are sug-
gestive of subclinical pulmonary oedema even in the absence of
signs and symptoms of overt pulmonary oedema. Acute hypoxia
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Table 3 Cardiorespiratory parameters pre-continuous positive airway pressure and during continuous positive airway
pressure (30 min) at Capanna Regina Margherita and Mount Everest South Base Camp
Capanna Regina Margherita Mount Everest South Base Camp D Pre-CPAP at CM vs. D
pre-CPAP at MEBC (P-value)
Pre-CPAP 300 CPAP P-value Pre-CPAP 300 CPAP P-value
HbO2-sat (%) 80 (78–81) 91 (84–97) ,0.001 81 (78–85) 80 (78–85) 0.80 ,0.001
HR (b.p.m.) 88 (77–101) 84 (77–86) ,0.001 76 (68–91)* 73 (63–85) 0.01 0.24
RR (b.p.m.) 17 (14–21) 16 (14–18) 0.79 13 (11–17) 13 (10–17) 0.52 0.62
SBP (mmHg) 126 (122–134) 130 (122–136) 0.89 131 (119–144) 132 (111–140) 0.23 0.61
DBP (mmHg) 87 (81–90) 90 (83–96) 0.57 80 (71–88) 84 (74–92) 0.26 0.51
PAPs (mmHg) 35 (31–40) 33 (24–35) 0.005 32 (27–40) 37 (33–38) 0.60 0.03
Data are reported as median and inter-quartile range (first and third quartiles). CPAP, continuous positive airway pressure; HbO2-sat, arterial haemoglobin saturation for oxygen;
HR, heart rate; RR, respiratory rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; PAPs, pulmonary artery systolic pressure. P-values represent significance vs. the
same parameter pre-continuous positive airway pressure in the same conditions.
*P, 0.05 vs. HR pre-continuous positive airway pressure at Capanna Regina Margherita.
Figure 1 Difference in arterial haemoglobin oxygen saturation
between pre-continuous positive airway pressure and during con-
tinuous positive airway pressure, after 5 and 30 min, respectively.
White columns are data collected at Capanna Regina Margherita,
grey columns are data collected at Mount Everest Base Camp.
*P, 0.000 vs. pre-continuous positive airway pressure condition.
Data are shown as median, first and third inter-quartiles and 95%
confidence interval values.
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may lead to transitory dysregulation of ventilation perfusion match-
ing which CPAP may counterbalance. Interestingly, Loeppky et al.29
showed that even in the first hours of hypobaric hypoxia there is,
at rest, a greater desaturation in the subjects developing acute
mountain sickness. It should be emphasized, however, that, both
at CM and MEBC, none of the subjects showed clinical evidence
of overt pulmonary oedema at the time of CPAP application.
Regardless of this, we observed that CPAP is effective in increasing
low arterial haemoglobin oxygen saturation, similar to when it is
applied during acute pulmonary oedema treatment at sea
level,16–18 but this occurs only after short-term exposure to high-
altitude hypobaric hypoxia. Furthermore, when CPAP was applied
in these acute hypoxic conditions, we observed not only a relevant
improvement in arterial haemoglobin oxygen saturation, but also a
reduction in heart rate and pulmonary artery pressure. All
together, these data are in line with the observations by
Cremona et al.10 and Grocott et al. suggesting that some subclinical
pulmonary oedema is present in many, if not all, subjects who
ascend rapidly to high altitudes and that CPAP can counterbalance
this lung fluid derangement.
A significant reduction in haemoglobin oxygen saturation was
also observed after short-term high-altitude exposure in the
HIGHCARE Mt Everest expedition, too. Furthermore, in the
acute phase of HIGHCARE expedition, during high-altitude
acclimatization, 5 out of the 47 European low-lander subjects
(none of whom, as required by the experimental protocol,
received any drugs to prevent HAPE, including acetazolamide)
experienced severe dyspnoea and other major clinical signs of
mountain sickness, which were treated using intravenous steroids,
inhalation of oxygen, acetazolamide and a temporary transfer to
lower altitude. During the 10-day permanence at MEBC, arterial
haemoglobin oxygen saturation improved in all subjects, suggesting
that adaptation to high altitudes was associated with a reduction in
alveolar extravascular fluid content. Indeed, when CPAP was
applied after 10 days of permanence at MEBC, no further haemo-
globin oxygen saturation changes were observed. The lack of
increase in haemoglobin oxygen saturation with CPAP after pro-
longed exposure at MEBC was not due to differences in baro-
metric pressure compared with CM, because, even if there is a
650 m altitude difference between CM and MEBC, the difference
in barometric pressure and therefore atmospheric partial PO2
was small, 40 and 8.4 mmHg, respectively, due to differences in lati-
tude.30,31 Furthermore, subjects treated at MEBC with higher
levels of CPAP did not show any increase in arterial haemoglobin
oxygen saturation. We interpret these findings as being due, with
permanence at high altitude, to an adaptation-induced reduction
in the amount of extravascular fluids acutely appearing on the
alveolar-capillary membrane, as suggested by the spontaneous hae-
moglobin oxygen saturation increase concomitantly occurring
during the stay at high altitudes (Figure 2). Finally, we can reason-
ably exclude the possibility that, under prolonged exposure to
high altitude, CPAP effects on blood oxygen saturation were pre-
vented by the chronic effects of pulmonary hypoxic vasoconstric-
tion, because after 7–10 days of permanence at high altitudes
pulmonary pressure was no longer elevated.
This study has several possible limitations that should be
acknowledged. First, differences in the laboratory settings should
be considered. Indeed, CM is a comfortably heated hut, whereas
experiments at MEBC were carried out, although on 2 sunny
days, in a heated tent. Second, we limited our observation to trans-
cutaneous haemoglobin oxygen saturation and did not perform
direct arterial gas analysis. Indeed, repeated arterial punctures
were found somehow unethical by researchers and difficult to
accept by volunteers. Third, we did not perform any direct
measurement of lung fluids or analysis of lung congestion as pre-
viously done by chest X-ray or spirometric techniques; so our sug-
gestions on lung fluid behaviour at altitude are indirectly derived
from arterial haemoglobin oxygen saturation changes. Fourth, we
did not measure ventilation at CM and at MEBC. It is known
that at high altitudes ventilation continues to increase over
2 weeks due to the increased sensitivity of peripheral
Figure 2 Arterial haemoglobin oxygen saturation (HbO2-sat),
heart rate, respiratory rate, pulmonary artery systolic pressure
and Lake Louise Score at Milan, Namche Bazar, and Mount
Everest South Base Camp at Days 1–2 and 10–11. Data are
shown as median, first and third inter-quartiles and 95% confi-
dence interval values. *P, 0.001 vs. Milan; %P, 0.01 vs. Milan;
§P, 0.001 vs. Namche Bazar; $P, 0.05 vs. Namche Bazar;
8P, 0.005 vs. Namche Bazar; #P, 0.001 vs. Mount Everest
South Base Camp Days 1–2.
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chemoreceptors to hypoxia.32 Because CPAP may act by increas-
ing ventilation, it is possible that at MEBC, after high-altitude adap-
tation, the supposed CPAP increase in ventilation is blunted,
reducing some of the CPAP effects seen at CM. Finally, we do
not know whether standard prophylactic treatment with acetazo-
lamide22 could influence the haemoglobin oxygen saturation
before and after CPAP application, an issue that would deserve
to be addressed in future studies at high altitudes.
In conclusion, this study suggests that after rapid high-altitude
ascent excessive fluids accumulate along the alveolar capillary
membrane affecting arterial haemoglobin oxygen saturation and
that, in these circumstances, CPAP is effective in increasing haemo-
globin oxygen saturation. This study also shows that acclimatization
implies an increase in haemoglobin oxygen saturation and a
reduction in heart rate, in parallel with a reduction in mountain
sickness symptoms. As a result, application of CPAP after long-
term high-altitude exposure is no longer associated with an
increase in arterial haemoglobin oxygen saturation. A practical
implication of our findings is that CPAP application could represent
a useful manoeuvre for the treatment of some mountain sickness
symptoms related to low blood oxygen saturation under acute
exposure to high-altitude hypobaric hypoxia. Even if our data
suggest that CPAP was no longer useful after prolonged high-
altitude exposure, in subjects without clinical signs or symptoms
of pulmonary oedema, we cannot exclude that CPAP very likely
remains a useful therapeutic tool in all cases of HAPE,33,34 regard-
less of the length of time subjects remain at high altitudes.
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A multi-modal assessment of a multi-visceral affect of a Wegener
granulomatosis
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A 34-year-old woman was hospitalized
for acute chest pain. Her personal
history was made of an acute inflam-
mation of the right lacrimal gland
(Panel A), biopsied 2 days before,
showing a non-specific inflammation.
EKG was normal, but troponin rose
up to 10 ng/mL, and C-reactive
protein to 200 mg/L. Renal function
was normal, without any proteinuria.
Transthoracic echo showed a septal
hypokinesia: left ventricular ejection
fraction (LVEF) 45%. A catheterization
was performed, showing normal cor-
onary arteries.
A cardiac 3 T MR examination was
achieved:
† Cine MR realized after the injection
of gadolinium confirmed the septal
hypokinesia (LVEF 38%), with a
contrast enhancement in the same
territory (Panel B).
† T1-weighted inversion recovery sequences, 10 min later, confirmed the septal inflammation: a delayed contrast enhanced is found in
the septal area, with a ‘patchy’ pattern (Panel C). Myocarditis was then diagnosed.
Since the thoracic radiography revealed several bilateral opacities (Panel D), a thoracic CT scan was achieved (Panels E and F ): bilateral
rounded opacities were found, some of them excavated, without any other anomalies. Transthoracic biopsies were performed, and
histological analysis showed ‘geographic’ necrosis with isolated multinucleated giant cells (Panel G), and leucocytoclastic vasculitis
(Panels H and I).
The research for cANCA was strongly positive (337 U/mL), and a Wegener granulomatosis was diagnosed, with myocardial, oph-
thalmological, and pneumological involvement. Corticosteroid therapy was introduced, allowing a quick improvement of the patient.
Cardiac involvement is a rare manifestation of Wegener granulomatosis. This case illustrates the need to use multi-modal imaging to
assess its extension.
Published on behalf of the European Society of Cardiology. All rights reserved.& The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.
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